Weihua Zhao

List of Publications by Year
in descending order

32 papers	4,591 citations	257357 24 h-index	477173 29 g-index
34 all docs	34 docs citations	34 times ranked	4244 citing authors

#	Article	IF	Citations
1	Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16021-16026.	3.3	647
2	CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15558-15563.	3.3	401
3	Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Experimental Neurology, 2012, 237, 147-152.	2.0	346
4	Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain, 2011, 134, 1293-1314.	3.7	323
5	Regulatory Tâ€lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Molecular Medicine, 2013, 5, 64-79.	3.3	289
6	Microglia in ALS: The Good, The Bad, and The Resting. Journal of NeuroImmune Pharmacology, 2009, 4, 389-398.	2.1	287
7	Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis. Journal of NeuroImmune Pharmacology, 2013, 8, 888-899.	2.1	253
8	Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2015, 12, 364-375.	2.1	236
9	Extracellular mutant SOD1 induces microgliaâ€mediated motoneuron injury. Glia, 2010, 58, 231-243.	2.5	232
10	TDP-43 activates microglia through NF-Î°B and NLRP3 inflammasome. Experimental Neurology, 2015, 273, 24-35.	2.0	174
11	Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain, Behavior, and Immunity, 2011, 25, 1025-1035.	2.0	170
12	Activated Microglia Initiate Motor Neuron Injury by a Nitric Oxide and Glutamate-Mediated Mechanism. Journal of Neuropathology and Experimental Neurology, 2004, 63, 964-977.	0.9	147
13	ALS patientsâ€™ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight, 2017, 2, e89530.	2.3	141
14	Mutant SOD1G93Amicroglia are more neurotoxic relative to wild-type microglia. Journal of Neurochemistry, 2007, 102, 2008-2019.	2.1	139
15	Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. Journal of Neurochemistry, 2006, 99, 1176-1187.	2.1	138
16	Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurology, 2017, 74, 677.	4.5	130
17	Expanded autologous regulatory T-lymphocyte infusions in ALS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e465.	3.1	116
18	Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiology of Disease, 2012, 48, 418-428.	2.1	109

#	Article	IF	Citations
19	Restoring regulatory T-cell dysfunction in Alzheimerâ€™s disease through ex vivo expansion. Brain Communications, 2020, 2, fcaa112.	1.5	48
20	Functional alterations of myeloid cells during the course of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 61.	4.4	44
21	Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Current Opinion in Neurology, 2021, 34, 765-772.	1.8	35
22	Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 15295.	1.6	34
23	Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 41.	2.5	32
24	Increased activation ability of monocytes from ALS patients. Experimental Neurology, 2020, 328, 113259.	2.0	30
25	Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls. IScience, 2020, 23, 101192.	1.9	27
26	The Role of Regulatory T Lymphocytes in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2018, 75, 656.	4.5	24
27	Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in <scp>ALS</scp>. Annals of Neurology, 2022, 92, 195-200.	2.8	14
28	Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation. Frontiers in Immunology, 0, 13, .	2.2	14
29	Serum programmed cell death proteins in amyotrophic lateral sclerosis. Brain, Behavior, & Immunity - Health, 2021, 12, 100209.	1.3	6
30	Novel therapeutic targets in neurodegenerative diseases: Lessons from amyotrophic lateral sclerosis. Current Neurology and Neuroscience Reports, 2008, 8, 353-355.	2.0	2
31	Role of Inflammation in Neurodegenerative Diseases. , 2015, , 380-395.		2
32	Reactive Oxygen and Nitrogen Species â€“ A Driving Force in Amyotrophic Lateral Sclerosis. , 2014, , 3141-3165.		0